MYCN and neuroblastoma: In summary, 25/663 CpGs can be selected by RFE and used to build the SVM model capable of stratifying NB patients based on MYCN amplification status, wherein these unique CpGs may be useful for building a diagnostic indicator for MYCN amplification in this cancer.